Enlivex Therapeutics (ENLV) said Wednesday it received a notice of allowance from the Japanese Patent Office for a patent application focused on the use of Allocetra in osteoarthritis patients.

The patent, which will secure the company's intellectual property rights in Japan until 2040, is expected to be officially issued by the end of Q2 2025, the company said.